Molbio Diagnostics forays into breast cancer screening through partnership with Niramai Health Analytix

Molbio Diagnostics, a pioneering in-vitro diagnostics (IVD) unicorn with a global footprint spread across over 70 countries through its Truenat platform, announced the launch of a strong collaboration with Niramai Health Analytix, a Bengaluru-based deep-tech startup. This partnership aims to accelerate the adoption of Niramai's innovative AI-based non-invasive breast cancer screening solution in developing countries around the world.

According to the World Health Organization (WHO), breast cancer is the most common cancer in the world and among top-5 deadliest of cancers globally. Although it affects people of all sexes, but it impacts women disproportionately – being among the leading causes of death in women and accounts for 24.5% of all new cancer cases in women worldwide. Late diagnosis of breast cancer is one of the challenges.

Portable point of care (POC) breast cancer screening solutions that enable efficient screening of large populations, especially in low resource settings, is a critical healthcare need across many geographies today. Niramai's Thermalytix is able to bridge these crucial gaps through its unique features.

Considering the high prevalence of breast cancer cases, it is important to screen populations at a large scale, which is possible only by deploying portable, non-invasive diagnostic devices like Thermalytix at point of care.

Thermalytix uses thermal scanning coupled with smart automated AI-enabled software that is able to detect early signs of breast cancer which otherwise would not have been detected through traditional methods. Another unique feature of Thermalytix is that it enables non- touch screening and is aligned with privacy needs of patients, thereby overcoming hesitation for breast examination. Additionally, this imaging method is radiation free, pain less and suitable to all age groups, even young women with dense breasts.

Through this collaboration, Molbio will promote and distribute Thermalytix in both public and private healthcare markets globally. The partnership builds on the strengths of the two companies to bring cutting-edge technology which would make high-quality diagnostics accessible to everyone.

Commenting on the collaboration, Sriram Natarajan, vice president - sales & marketing of Molbio commented, “We are thrilled to add another cap to our universal access portfolio of innovative healthcare solutions. Niramai’s AI-based Thermalytix device for breast cancer and Molbio’s Truenat HPV-HR test for cervical cancer will enable point of care screening and early detection of the two most deadly cancers of women worldwide, saving millions of lives.”

Highlighting the benefit of the collaboration Dr Geetha Manjunath, founder and CEO of Niramai Health Analytix said, “We are very excited to announce this partnership which has the potential to take our affordable and automated breast screening test to every lady, world over and improve health equity.”

Molbio Diagnostics is India’s first ‘unicorn’ in the medical technology sector that brings to healthcare professionals worldwide the Truelab Real-Time Quantitative micro-PCR system comprising Truenat technology that makes Real-Time PCR testing possible in all laboratories, in the field and near-patient settings. With a large and growing menu of Truenat assays for infectious diseases, including TB, Covid-19, HIV, HCV, HBV, HPV, Influenza, etc., this rapid, portable technology enables early and accurate diagnosis and initiation of correct treatment right at the first point of contact. So far, the platform is deployed in over 6,000 PHC/CHCs in India and over 1500 testing centres in over 70 countries around the world.

Molbio currently has partnerships with SigTuple, ShanMukha Innovations and a majority stake in Prognosys Medical Systems.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!